Cargando…

Prevalence of thyroid disorders in hepatitis C virus positive patients on interferon and antiviral therapy

BACKGROUND: Hepatitis C virus (HCV) infection is common worldwide. The treatment typically involves a combination of interferon-alpha (IFN-α) and ribavirin (RBV) therapy; however, the use of IFN-α is well documented to be associated with thyroid disease, the most common autoimmune disorder associate...

Descripción completa

Detalles Bibliográficos
Autores principales: Goyal, Gitanjali, Panag, KMDS, Garg, Ravinder
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5108099/
https://www.ncbi.nlm.nih.gov/pubmed/27857890
http://dx.doi.org/10.4103/2229-516X.192587
_version_ 1782467304822407168
author Goyal, Gitanjali
Panag, KMDS
Garg, Ravinder
author_facet Goyal, Gitanjali
Panag, KMDS
Garg, Ravinder
author_sort Goyal, Gitanjali
collection PubMed
description BACKGROUND: Hepatitis C virus (HCV) infection is common worldwide. The treatment typically involves a combination of interferon-alpha (IFN-α) and ribavirin (RBV) therapy; however, the use of IFN-α is well documented to be associated with thyroid disease, the most common autoimmune disorder associated with IFN-α. AIM: The aim of the present study was to know the prevalence of thyroid abnormality in the HCV-positive patients on IFN and antiviral therapy. MATERIALS AND METHODS: Fifty known HCV positive patients were enrolled for the study. All the patients were on IFN (3 million unit subcutaneously 3 times/week) and antiviral therapy (oral RBV 1000–1200 mg/day). Thyroid function tests were performed first at the start of treatment and then after 12 weeks of treatment. RESULTS: 13 (26%) of the patients were found to develop hypothyroidism, and 1 (2%) patient developed hyperthyroidism in the course of 12 weeks therapy. CONCLUSION: HCV patients on IFN and antiviral therapy have an effect on the thyroid gland, so these patients should be regularly screened for thyroid disorders and appropriately treated to maintain euthyroid status.
format Online
Article
Text
id pubmed-5108099
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-51080992016-11-17 Prevalence of thyroid disorders in hepatitis C virus positive patients on interferon and antiviral therapy Goyal, Gitanjali Panag, KMDS Garg, Ravinder Int J Appl Basic Med Res Original Article BACKGROUND: Hepatitis C virus (HCV) infection is common worldwide. The treatment typically involves a combination of interferon-alpha (IFN-α) and ribavirin (RBV) therapy; however, the use of IFN-α is well documented to be associated with thyroid disease, the most common autoimmune disorder associated with IFN-α. AIM: The aim of the present study was to know the prevalence of thyroid abnormality in the HCV-positive patients on IFN and antiviral therapy. MATERIALS AND METHODS: Fifty known HCV positive patients were enrolled for the study. All the patients were on IFN (3 million unit subcutaneously 3 times/week) and antiviral therapy (oral RBV 1000–1200 mg/day). Thyroid function tests were performed first at the start of treatment and then after 12 weeks of treatment. RESULTS: 13 (26%) of the patients were found to develop hypothyroidism, and 1 (2%) patient developed hyperthyroidism in the course of 12 weeks therapy. CONCLUSION: HCV patients on IFN and antiviral therapy have an effect on the thyroid gland, so these patients should be regularly screened for thyroid disorders and appropriately treated to maintain euthyroid status. Medknow Publications & Media Pvt Ltd 2016 /pmc/articles/PMC5108099/ /pubmed/27857890 http://dx.doi.org/10.4103/2229-516X.192587 Text en Copyright: © 2016 International Journal of Applied and Basic Medical Research http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.
spellingShingle Original Article
Goyal, Gitanjali
Panag, KMDS
Garg, Ravinder
Prevalence of thyroid disorders in hepatitis C virus positive patients on interferon and antiviral therapy
title Prevalence of thyroid disorders in hepatitis C virus positive patients on interferon and antiviral therapy
title_full Prevalence of thyroid disorders in hepatitis C virus positive patients on interferon and antiviral therapy
title_fullStr Prevalence of thyroid disorders in hepatitis C virus positive patients on interferon and antiviral therapy
title_full_unstemmed Prevalence of thyroid disorders in hepatitis C virus positive patients on interferon and antiviral therapy
title_short Prevalence of thyroid disorders in hepatitis C virus positive patients on interferon and antiviral therapy
title_sort prevalence of thyroid disorders in hepatitis c virus positive patients on interferon and antiviral therapy
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5108099/
https://www.ncbi.nlm.nih.gov/pubmed/27857890
http://dx.doi.org/10.4103/2229-516X.192587
work_keys_str_mv AT goyalgitanjali prevalenceofthyroiddisordersinhepatitiscviruspositivepatientsoninterferonandantiviraltherapy
AT panagkmds prevalenceofthyroiddisordersinhepatitiscviruspositivepatientsoninterferonandantiviraltherapy
AT gargravinder prevalenceofthyroiddisordersinhepatitiscviruspositivepatientsoninterferonandantiviraltherapy